Esperion 治療公司
US ˙ NasdaqGM ˙ US29664W1053

SecurityESPR / Esperion Therapeutics, Inc.
InstitutionElkfork Partners LLC
Latest Disclosed Ownership11,220 shares
Latest Disclosed Value $ 411,000
Elkfork Partners LLC reports 0.90% decrease in ownership of ESPR / Esperion Therapeutics, Inc.

On November 14, 2019 - Elkfork Partners LLC filed a 13F-HR form disclosing ownership of 11,220 shares of Esperion Therapeutics, Inc. (US:ESPR) valued at $411,325 USD as of September 30, 2019. The entity filed a previous 13F-HR on August 13, 2019 disclosing 11,322 shares of Esperion Therapeutics, Inc.. This represents a change in shares of -0.90% during the quarter. The current value of the position is $35,119 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2019-11-14 2019-09-30 13F Esperion Therapeutics COM 29664W105 11,220 -102 -0.90 411 -22.01 0.0100
2019-08-13 2019-06-30 13F Esperion Therapeutics COM 29664W105 11,322 -2,958 -20.71 527 -8.03 0.0129
2019-05-13 2019-03-31 13F Esperion Therapeutics COM 29664W105 14,280 442 3.19 573 -9.91 0.0144
2019-02-13 2018-12-31 13F Esperion Therapeutics COM 29664W105 13,838 -2,822 -16.94 636 -13.94 0.0179
2018-11-14 2018-09-30 13F Esperion Therapeutics COM 29664W105 16,660 14,450 653.85 739 749.43 0.0176
2018-08-13 2018-06-30 13F Esperion Therapeutics COM 29664W105 2,210 -19,244 -89.70 87 -94.39 0.0022
2018-05-10 2018-03-31 13F Esperion Therapeutics COM 29664W105 21,454 16,252 312.42 1,552 353.80 0.0418
2018-02-24 2017-12-31 13F/A-1 Esperion Therapeutics COM 29664W105 5,202 -3,774 -42.05 342 -24.00 0.0093
2017-11-14 2017-09-30 13F Esperion Therapeutics COM 29664W105 8,976 -1,088 -10.81 450 -3.43 0.0131
2017-08-14 2017-06-30 13F Esperion Therapeutics COM 29664W105 10,064 -3,400 -25.25 466 -1.89 0.0140
2017-05-03 2017-03-31 13F Esperion Therapeutics COM 29664W105 13,464 0 0.00 475 181.07 0.0146
2017-02-10 2016-12-31 13F Esperion Therapeutics COM 29664W105 13,464 13,464 169 0.0056
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.